Equity Profile

CTNM

Contineum Therapeutics, Inc.

Health CarePharmaceuticals$504.3M

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Contineum Therapeutics, Inc. operates in the health care sector, focusing on pharmaceuticals....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, which is vital for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CTNM Q2-2026 Earnings Preview

Context

Company Snapshot

Contineum Therapeutics, Inc. operates in the health care sector, focusing on pharmaceuticals. With a market cap of $1 billion, the company plays a crucial role in developing innovative therapies that could address unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+1.76%

Avg Stock Reaction

-0.13%

Last Quarter Recap

In the last quarter, Contineum reported an EPS of -$0.39, which was better than the estimated -$0.55, resulting in a positive surprise. The stock saw a slight increase of 1.70% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, there is uncertainty surrounding Contineum's upcoming earnings report, as analysts do not have specific estimates available. Investors are keen to see if the company can continue its trend of beating EPS estimates.

Bull Case

If Contineum can report a smaller loss than expected and show signs of revenue growth, it could boost investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in the stock price, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure is crucial for assessing the company's financial performance and could significantly impact investor sentiment.

What insights can management provide on revenue growth?

Understanding revenue trends will help investors gauge the company's market position and future potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Contineum's potential for a smaller loss this quarter, given its recent trend of beating EPS estimates.

Supporting Evidence

The company has a 63% EPS beat rate over the last eight quarters, indicating a pattern of positive surprises.

Options are pricing in a significant move of 25.8%, suggesting that traders expect volatility, which could indicate underlying confidence.

The stock has historically reacted positively to earnings surprises, even when the EPS was negative.

Key Risk

If the EPS comes in better than -$0.39, it could shift market sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on whether Contineum can continue to improve its earnings and revenue metrics.

Bull Confirmed If

A reported EPS loss of less than -$0.39 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.39 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±25.8%

Historical Avg

±4.0%

Pricing rich

The options market is pricing in a significant potential move of nearly 26%, indicating that traders expect volatility around the earnings report.

Options are pricing ±25.8% while CTNM has averaged ±4.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.3%

30d HV

58.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Contineum beats expectations, history suggests the stock could rise by around 3.1%, confirming a positive outlook.

In-Line / Cautious

If results are in line with previous quarters, the stock may see muted movement as investors await further guidance.

Miss

If the company misses expectations, the stock could drop by about 0.1%, reflecting disappointment in performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or clinical trial results.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for their pharmaceutical products.
4Details on any partnerships or collaborations that may impact growth.
5Guidance on expected revenue for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Contineum Therapeutics, Inc. operates in the health care sector, focusing on pharmaceuticals....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, which is vital for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CTNM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+1.76%

Avg Stock Reaction

-0.13%

Last Quarter Recap

In the last quarter, Contineum reported an EPS of -$0.39, which was better than the estimated -$0.55, resulting in a positive surprise. The stock saw a slight increase of 1.70% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Contineum can report a smaller loss than expected and show signs of revenue growth, it could boost investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in the stock price, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure is crucial for assessing the company's financial performance and could significantly impact investor sentiment.

What insights can management provide on revenue growth?

Understanding revenue trends will help investors gauge the company's market position and future potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Contineum's potential for a smaller loss this quarter, given its recent trend of beating EPS estimates.

Supporting Evidence

The company has a 63% EPS beat rate over the last eight quarters, indicating a pattern of positive surprises.

Options are pricing in a significant move of 25.8%, suggesting that traders expect volatility, which could indicate underlying confidence.

The stock has historically reacted positively to earnings surprises, even when the EPS was negative.

Key Risk

If the EPS comes in better than -$0.39, it could shift market sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on whether Contineum can continue to improve its earnings and revenue metrics.

Bull Confirmed If

A reported EPS loss of less than -$0.39 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.39 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±25.8%

Historical Avg

±4.0%

Pricing rich

The options market is pricing in a significant potential move of nearly 26%, indicating that traders expect volatility around the earnings report.

Options are pricing ±25.8% while CTNM has averaged ±4.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.3%

30d HV

58.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Contineum beats expectations, history suggests the stock could rise by around 3.1%, confirming a positive outlook.

In-Line / Cautious

If results are in line with previous quarters, the stock may see muted movement as investors await further guidance.

Miss

If the company misses expectations, the stock could drop by about 0.1%, reflecting disappointment in performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or clinical trial results.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for their pharmaceutical products.
4Details on any partnerships or collaborations that may impact growth.
5Guidance on expected revenue for the next quarter.